Tag
Pharma / Healthcare
94 articles
The healthcare sector is demonstrating a mix of strategic growth and regulatory navigation. Several companies are focused on expanding capabilities and market reach, exemplified by Ind-Swift Laboratories' ₹45 crore investment to upgrade its Jammu facility, targeting ₹100 crore in annual revenue from European markets, and Piramal Pharma's acquisition of a 40.67% stake in Yapan Bio to bolster its large molecule CDMO services. Meanwhile, Hims & Hers is defending an FTC lawsuit concerning data sharing practices, while Colgate-Palmolive India achieved a significant milestone with the ISP Seal of Acceptance for its PerioGard gum care portfolio, setting a new standard for oral health solutions in India. These developments highlight the ongoing evolution of healthcare business models and the increasing importance of regulatory compliance and evidence-based practices.
Hims & Hers CEO Defends FTC Lawsuit
FTC, Los Angeles County and Utah sued Hims & Hers in July over alleged health data sharing with Meta and Snap, prescription charging before provider consultation, and difficult subscription cancellati
Alkem Laboratories Petition Withdrawn by HC
The Gujarat High Court disposed Special Civil Application No.16885/2025 filed by Alkem Laboratories Ltd against Dakshin Gujarat Vij Co. Ltd, granting withdrawal.
The petition was withdrawn on 17 Augus
Ind-Swift Jammu Facility EUGMP Upgrade Targets ₹100 Cr Revenue
Ind-Swift Laboratories upgrading Jammu facility to EU-GMP/PICS standards with ₹45 crore investment to access regulated markets.
Facility expected to generate additional ₹100 crore revenue annually fro
Jeena Sikho Lifecare Publishes Six Ayurvedic Case Studies
Jeena Sikho Lifecare intimated exchanges about publishing six medical case studies in peer-reviewed journals.
The studies cover Ayurvedic management of infertility, chronic kidney disease, and piles.
Colgate PerioGard Earns ISP Seal of Acceptance
Colgate-Palmolive India's PerioGard gum care portfolio received the Indian Society of Periodontology Seal of Acceptance, marking the first such recognition in India.
The ISP Seal validates product saf
Strides Pharma 35th AGM Approves All Resolutions
Strides Pharma Science held its 35th AGM on August 14, 2026 via video conferencing, passing all six proposed resolutions with requisite majority.
Shareholders approved a final dividend for FY2026 and
Hexagon Nutrition Q1 FY27 Revenue Up 43.2% YoY
Hexagon Nutrition reported Q1 FY27 consolidated revenue of INR104.3 crore, up 43.2% YoY, with PAT growing 25.1% to INR8.1 crore.
Management held an earnings call to discuss results, highlighting stron
Blue Jet Healthcare 58th AGM Notice with Resolutions
Blue Jet Healthcare issued notice for its 58th AGM to be held virtually on September 21, 2026.
Key resolutions include declaring a ₹1.20 dividend and re-appointing two key directors for five-year term
Piramal Pharma Acquires 40.67% Additional Yapan Bio Stake
Piramal Pharma completed acquisition of 1,46,400 Yapan Bio shares for ₹76 crores, increasing stake from 33.33% to 74.00%.
Yapan Bio transitions from associate to subsidiary company, specializing in va
Mancare Laboratories Seeks SC Special Leave
Supreme Court heard petition by Mancare Laboratories Pvt Ltd seeking special leave to appeal against Chhattisgarh High Court judgment dated 06-07-2026.
The matter was listed for disposal on 22 Sep 202
Mankind Pharma Releases 38.68% BSVL Share Pledge
Mankind Pharma completed the realignment of security cover for its Non-Convertible Debentures (NCDs) as per board approval.
The company released the pledge on 28,280 equity shares of Bharat Serums and
Bacil Pharma Board Meeting on Director Appointment
Bacil Pharma Limited intimates BSE of a scheduled board meeting on August 25, 2026.
The board will discuss and propose resolutions for the appointment of directors.
The intimation is a regulatory comp
Supreme Court Sets Hearing for Nectar Labs Appeal
Petitioner K. Venugopal Reddy filed Special Leave to Appeal (C) No.47/2026 against Nectar Laboratories Ltd, contesting a 26‑09‑2025 High Court order.
Court waived notice for respondents 1‑2, issued no
Jubilant Pharmova Shareholders Approve MD Reappointments
Jubilant Pharmova shareholders approved the re-appointment of Priyavrat Bhartia as Managing Director via postal ballot with 99.81% votes in favor.
Shareholders also approved Arjun Shanker Bhartia's re
Jeena Sikho Publishes 7 Ayurvedic Medical Case Studies
Jeena Sikho Lifecare intimated publication of 7 Ayurvedic medical case studies in international journals under SEBI LODR Regulation 30.
Case studies cover chronic conditions like kidney disease, diabe
Fredun Pharmaceuticals NSE Listing Effective August 17
Fredun Pharmaceuticals equity shares permitted for trading on NSE from August 17, 2026.
Listing follows NSE Circular Ref. No. 1355/2026 dated August 14, 2026.
Company maintains existing BSE listing wi
Shukra Pharmaceuticals NSE Listing Media Coverage Disclosure
Shukra Pharmaceuticals discloses ANI media coverage regarding its NSE listing on August 14, 2026.
Article highlights company's strategic focus on Medical Technology, AI, and healthcare innovation.
Com
Alkem Laboratories Shareholders Approve Adroit Biomed Amalgamation
Alkem Laboratories shareholders approved the amalgamation with Adroit Biomed via a court-convened meeting held on August 17, 2026.
The resolution passed with near-unanimous 99.9999% votes in favor, re
Ind-Swift Laboratories Q1 FY27 Earnings Call Recording
Ind-Swift Laboratories made Q1 FY27 earnings call audio recording available on investor relations website.
Company will share transcript with stock exchanges and upload to website in due course.
Discl
Orchid Pharma Q1 FY27 Results Analyst Call
Orchid Pharma schedules Q1 FY27 results analyst call for August 21, 2026, hosted by Systematix Institutional Equities.
Management participants include MD Manish Dhanuka, Whole Time Director Mridul Dha
Gufic Biosciences Q1 FY27 Earnings Call Recording
Gufic Biosciences submitted audio recording of its Q1 FY27 earnings conference call held on August 17, 2026 to BSE and NSE.
The recording was uploaded to company website pursuant to SEBI Listing Regul
P&G Hygiene FY26 Revenue ₹4,290 Crore, PAT Up 19%
P&G Hygiene reported FY26 revenue of ₹4,290 crore with 19% PAT growth to ₹857 crore, driven by health and hygiene product performance.
The Board recommended a final dividend of ₹60 per share, bringing
Aptus Pharma Approves ₹44.88 Crore Preferential Issue
Aptus Pharma board approved a preferential issue of 16.02 lakh equity shares at ₹280 per share, raising ₹44.88 crores.
The board approved the final list of 190 allottees and set the issue price based
Fermenta Biotech Intimates August 21 Investor Meetings
Fermenta Biotech will hold one-to-one physical investor meetings in Mumbai on August 21, 2026.
The company stated no unpublished price sensitive information will be shared during these interactions.
R
Tarsons Q1 FY27 Revenue Up 21% YoY
Tarsons Products Limited reported Q1 FY27 consolidated revenue of INR 110.2 crores, a 20.7% YoY growth, driven by strong domestic and export recovery.
EBITDA margin moderated to 23.6% due to sharp raw
Themis Medicare Updates Compliance Officer, RTA Email IDs
Themis Medicare Ltd filed a regulatory disclosure to BSE and NSE updating official contact emails for investor communications.
The company changed its Company Secretary/Compliance Officer's email from
Fredun Pharmaceuticals Q1 FY27 Revenue Jumps 90%
Fredun Pharmaceuticals reported Q1 FY27 standalone revenue of ₹228.25 crore, a 90.44% YoY growth, with net profit up 94.63% to ₹13.17 crore.
Management outlined a 3-5 year growth trajectory of 30-35%,
Zydus Lifesciences Announces Singapore-Hong Kong Investor Roadshow
Zydus Lifesciences management will conduct a Non-Deal Roadshow with investors in Singapore and Hong Kong from August 24-26, 2026.
The company filed this intimation with BSE and NSE as a regulatory dis
NGL Fine-Chem Q1FY27 PAT Up 99% YoY
NGL Fine-Chem reported Q1FY27 PAT of ₹18.40 crore, up 36.4% QoQ and 99.1% YoY, driven by robust demand and forex gains.
Revenue from operations stood at ₹139.16 crore, up 33.6% YoY, with Animal API se
Dishman Carbogen Amcis Allots ₹75 Crore NCDs
Dishman Carbogen Amcis Ltd's Management Committee approved the allotment of 7,500 NCDs worth ₹75 crore on a private placement basis.
The Senior, Secured, Rated, Listed NCDs have a face value of ₹1,00,
Indegene FY26 Revenue Up 23.6% to ₹35.1B
Held 28th Annual General Meeting via video conference, presenting FY2025-26 financial results and strategic updates.
Reported revenue growth of 23.6% to ₹35,105 million with PAT of ₹4,011 million and
Lupin Receives US FDA Approval for Pitolisant Tablets
Lupin received final FDA approval for its generic Pitolisant Tablets in 4.45 mg and 17.8 mg strengths.
The approval confirms bioequivalence to Wakix® for all indications in the approved labeling.
This
Godavari Drugs Reports No Fund Utilization Deviation Q1 FY27
Godavari Drugs Limited files a mandatory SEBI Regulation 32 statement confirming no deviation in use of ₹4,411.73 lakh funds raised via preferential issue on 18-Mar-2026.
The company utilized ₹763.27
TCS Launches Agentic AI Platform for Drug Development
TCS launched TCS ADD™ AgentHub, an enterprise-ready AI platform for pharmaceutical drug development and clinical trials.
The platform demonstrated up to 40% efficiency gains in clinical data managemen
Veerhealth Care Q1FY27 Revenue Soars 388% YoY
Veerhealth Care reported Q1FY27 standalone revenue of ₹25.09 crore, up 388.13% YoY, with PAT of ₹1.23 crore up 412.50% YoY.
Company announced four major export orders totaling approximately ₹32.33 cro
Aurobindo Pharma US FDA Raleigh Plant VAI Classification
Aurobindo Pharma's US subsidiary Aurolife Pharma received VAI classification from US FDA for its Raleigh plant after March-April 2025 inspection.
The facility received 11 observations in Form 483 but
Natco Pharma Intimates Nuvama ICICI Investor Meet
Natco Pharma intimates participation in a three-day group investor meeting in Mumbai organized by Nuvama and ICICI Securities.
The in-person meeting is scheduled from August 19th to 21st, 2026, from 9
West Bengal PM Jan Aushadhi Kendra Coverage Report
PMBI confirms no proposal received from West Bengal for 469 new Jan Aushadhi Kendras expansion.
West Bengal has 1,014 operational JAKs with 715 located across 217 blocks as of June 2026.
128 out of 34
PMBJP Reaches 20,149 Jan Aushadhi Kendras by June 2026
The Ministry of Chemicals and Fertilizers reported 20,149 PMBJP Jan Aushadhi Kendras operational nationwide as of June 30, 2026.
Uttar Pradesh leads with 4,226 Kendras, followed by Karnataka (1,720) a
PMBJP Medicine Sales Reach ₹4,274 Crore Over Two Years
PMBJP achieved total sales of ₹4,274.66 crore at MRP during FY2024-25 and FY2025-26, with ₹2,252.19 crore in the most recent year.
77 Jan Aushadhi Kendras operational in Himachal Pradesh as of June 20
Viyash Scientific Q1 FY27 Revenue Up 20% YoY
Viyash Scientific reported Q1 FY27 revenue of ₹946 crore, up 20% YoY, with EBITDA surging 59% to ₹205 crore.
Net debt reduced to ₹86 crore, with net debt/EBITDA at 0.1x, providing flexibility for expa
AstraZeneca Pharma India Schedules August 19 Investor Meeting
AstraZeneca Pharma India intimates a scheduled one-on-one virtual meeting with an institutional investor on August 19, 2026.
The disclosure is made pursuant to Regulation 30 of SEBI LODR Regulations,
Lincoln Pharma Q1 FY27 Net Profit Rises 31% YoY
Lincoln Pharmaceuticals reported Q1 FY27 consolidated net profit of ₹36.23 crore, up 30.9% YoY from ₹27.68 crore in Q1 FY26.
Total income for the quarter stood at ₹201.55 crore, a 19.02% YoY increase,
RPG Life Sciences API Chief Moves to Subsidiary
Mr. Deepak Shukla resigned as Chief Executive - API Business of RPG Life Sciences effective August 14, 2026.
His resignation is due to appointment as CEO of wholly-owned subsidiary RPG Active Pharma L
RPG Life Sciences Completes API Business Transfer
RPG Life Sciences completed the slump sale transfer of its Active Pharmaceuticals Ingredients business to wholly-owned subsidiary RPG Active Pharma Limited.
The transaction was executed under a Busine
Anlon Healthcare 13th AGM Approves Major Acquisitions and Capital Restructuring
Anlon Healthcare Limited convenes its 13th Annual General Meeting on September 5, 2026 via video conference to approve eleven resolutions including financial statements adoption.
Key proposals include
Dr. Reddy's USFDA Inspection Concludes with Four Observations
USFDA completed a GMP inspection at Dr. Reddy's Bachupally formulations plant from August 6-14, 2026.
The inspection resulted in a Form 483 issuance containing four observations for the facility.
Dr.
Dr. Reddy's UK API Facility USFDA Inspection Closed VAI
USFDA closed its GMP inspection at Dr. Reddy's UK API facility with a Voluntary Action Indicated (VAI) classification.
The inspection, conducted at the Mirfield, West Yorkshire facility, is officially
Cipla vs NPPA: SC Allows 4‑Week Extension
Supreme Court heard Cipla's petition for special leave to appeal against NPPA order dated 24‑04‑2026.
Court granted the respondent's Additional Solicitor General four weeks to file a counter‑affidavit
Anuh Pharma 66th AGM Voting Results Approval
Anuh Pharma held its 66th AGM virtually on August 12, 2026, with 45 shareholders attending via video conference.
Shareholders approved all nine resolutions, including a ₹1.50 per share dividend and re
Rubicon Research Q1 FY2027 Earnings Call Recording
• Rubicon Research Limited published audio recording of Q1 FY2027 earnings conference call held on August 14, 2026.
• The disclosure complies with SEBI LODR Regulations 30 and 46 regarding corporate a
Poly Medicure Q1 FY27 Revenue Up 30.3% YoY
Poly Medicure reported Q1 FY27 consolidated revenue of INR525 crore, up 30.3% YoY, with organic growth at 12.4%.
The company outlined its PolyMed 3.0 strategic vision to double revenue by FY30 through
Multiple Companies File Q1 FY2027 Financial Results
Future Market Networks and other listed entities submitted quarterly financial results for June 30, 2026 to BSE/NSE under SEBI LODR Regulation 33.
Ipca Laboratories reported strong consolidated perfor
Norris Medicines Q1 FY27 Net Loss ₹39.68 Lakh
Norris Medicines reported a Q1 FY27 net loss of ₹39.68 lakh, a decline from a ₹5.06 lakh profit in Q4 FY26.
The Board approved the reappointment of Vimal D. Shah as Managing Director for a three-year
Aarey Drugs Q1 FY27 Net Profit ₹1.02 Crore
Aarey Drugs reported Q1 FY27 standalone net profit of ₹1.02 crore on revenue of ₹102.03 crore, with EPS of ₹0.36.
The board approved unaudited financial results for quarter ended June 30, 2026, follow
Fischer Medical Ventures Q1 FY27 Net Loss Widens
Fischer Medical Ventures reported a standalone net loss of ₹350.41 lakhs for Q1 FY27, significantly widening from a ₹60.94 lakh loss in Q1 FY26.
The Board approved the allotment of 2.05 crore equity s
Alembic Pharma SLA Petition Adjourned to Aug 31
Supreme Court heard Alembic Pharmaceuticals' Special Leave to Appeal against State of Gujarat on 10 Aug 2026.
The bench comprising Justices Pamidighantam, Sri Narasimha and Alok Aradhe ordered adjourn
Ortin Global Q1 FY27 Net Loss ₹33.79 Lakh
Ortin Global reported a standalone net loss of ₹33.79 lakh for Q1 FY27, with revenue from operations at just ₹1.16 lakh.
The company's Other Equity remains deeply negative at ₹(689.43) lakh, indicatin
Supreme Court Dismisses Sanjay Jain SLP
Supreme Court heard SLP No. 26804/2026 on 14 Aug 2026, filed by Sanjay Jain against Shree Vishwanath Marwari Databya Aushadhalaya.
The petition challenged the Gauhati High Court’s final judgment dated
Alkem Laboratories Q1FY27 Earnings Call Recording Available
Alkem Laboratories intimated availability of Q1FY2027 earnings conference call audio recording on its investor website.
The disclosure is a compliance filing with BSE and NSE under SEBI LODR Regulatio
Natco Pharma Q1 FY27 Earnings Call Audio Link
Natco Pharma provided audio weblink for Q1 FY26-27 earnings conference call held on August 14, 2026.
The audio recording is available on company website as regulatory compliance under SEBI LODR Regula
Neuland Laboratories Receives US FDA Form 483
Neuland Laboratories discloses US FDA inspection of its Unit 3 facility from August 10-14, 2026.
US FDA issued a Form 483 with one observation on procedural water and environmental monitoring improvem
Lasa Supergenerics Q1 FY27 Net Loss ₹357.87 Lakh
Lasa Supergenerics reported a standalone net loss of ₹357.87 lakh for Q1 FY27, with operations completely halted since a May 2025 factory fire.
The company faces severe operational disruption, unable
Gaudium IVF Q1 FY27 Earnings Call Recording Uploaded
Gaudium IVF uploaded the audio recording of its Q1 FY27 earnings call held on August 14, 2026.
The call discussed unaudited standalone and consolidated financial results for quarter ended June 30, 202
Natco Pharma Q1 FY27 Net Profit INR 2,065 Million
Natco Pharma reported Q1 FY27 consolidated revenue of INR 7,944 million with a net profit of INR 2,065 million and an EBITDA margin of 30.9%.
Profit share from associate Adcock Ingram Holdings contrib
Ipca Laboratories Q1 FY27 Earnings Conference Call
Ipca Laboratories held Q1 FY27 earnings conference call on August 14, 2026 from 15:30 IST.
Audio recording of the earnings call made available on company's shareholder information webpage.
Disclosure
Ajooni Biotech Q1 Net Profit Drops 54% YoY
• Ajooni Biotech reported Q1 FY27 standalone revenue of ₹634.91 lakh, up 103% YoY from ₹312.68 lakh.
• Net profit for the quarter fell 54% YoY to ₹43.18 lakh, with finance costs rising substantially t
Supriya Lifescience Q1 FY27 Earnings Call Recording
Supriya Lifescience made the audio recording of its Q1 FY27 earnings call available on its investor relations website.
The call, held on August 14, 2026, discussed the company's operational and financ
Rubicon Q1 Revenue Up 51.6% YoY, PAT Jumps 95.8%
Q1 FY27 revenue grew 51.6% YoY to ₹5,343 Mn with PAT surging 95.8% to ₹848 Mn, driven by a broad-based portfolio.
Operating EBITDA margin expanded to 24.2% despite cost pressures, with the company upg
Medico Intercontinental Q1 FY27 Standalone Profit ₹60.76 Lakh
Board approved unaudited standalone and consolidated financial results for Q1 FY27 ending June 30, 2026.
Standalone performance showed net profit of ₹60.76 lakhs on revenue of ₹1524.02 lakhs.
Consolid
Windlas Biotech Q1 FY27 Revenue Hits Record ₹248 Crore
Windlas Biotech reported its highest-ever quarterly revenue of ₹248 crore, an 18% YoY growth, marking 14 consecutive quarters of record revenue.
The company completed a ₹47 crore buyback and declared
Deccan Health Care Q1 FY27 Net Profit Drops 60% YoY
Deccan Health Care reported Q1 FY27 standalone net profit of ₹24.63 lakh, a 60% decline from ₹61.63 lakh in Q1 FY26.
Consolidated revenue grew 8.3% YoY to ₹2,447.62 lakh, while expenses increased 10.5
Godavari Drugs Q1 Net Profit Rises 6.6% YoY
Godavari Drugs reported un-audited Q1 FY2027 standalone results with revenue of ₹27.96 crore and net profit of ₹1.11 crore.
Net profit increased 6.6% YoY to ₹1.11 crore, while revenue grew 17.4% YoY,
Godavari Drugs Q1 Net Profit Rises 6.6% YoY
Board approved Q1 FY27 un-audited financial results showing revenue of ₹2795.72 lakh and net profit of ₹110.91 lakh.
Allotted 7,86,690 equity shares to promoters upon conversion of warrants, raising ₹
Mihir Shah Acquires 3.77 Lakh Parnax Lab Shares via Gift
Mihir Shah, a promoter of Parnax Lab, acquired 377,355 equity shares from fellow promoter Baiju Shah via inter-se gift transfer on July 21, 2026.
The transaction falls under SEBI Takeover Regulations
Gaudium IVF Q1 FY27 Revised Investor Presentation
Gaudium IVF submitted a revised investor presentation for Q1 FY27, correcting and adding disclosures on Adjusted EBITDA margins and a one-time marketing expense.
The standalone Adjusted EBITDA was cor
Supriya Lifescience Q1 FY27 Revenue Up 31% YoY
Supriya Lifescience reported Q1 FY27 unaudited results with revenue growth of 30.8% YoY to ₹189.75 crore but PAT declined 30.9% to ₹24.04 crore.
Export contribution remained strong at 81% of revenue,
Alpa Laboratories Q1 Net Profit Falls 92% YoY
Board approved unaudited standalone and consolidated financial results for Q1 June 2026 showing significant profit decline.
Standalone net profit dropped to ₹1.04 crore from ₹11.78 crore YoY due to lo
Dr. Padma Gurmet Receives UT Ladakh State Award 2025
Dr. Padma Gurmet, Director of National Institute of Sowa-Rigpa, conferred UT Ladakh State Award 2025 for Sowa-Rigpa medicine contributions.
Lieutenant Governor Vinai Kumar Saxena presented awards to 3
Colinz Laboratories Open Offer for 26% at ₹54/share
Saffron Capital issued a reminder advertisement for an open offer by Annjana Dugar, Likhitta Dugar, and Antariksh Dugar with PAC Padam Dugar to acquire 654,966 shares (26%) of Colinz Laboratories at ₹
Anuh Pharma Promoters Withdraw Reclassification Request
Anuh Pharma Ltd discloses withdrawal of application to reclassify three promoter group members from 'Promoter' to 'Public' category.
Vikram Kirtilal Shah, Kiran Piyush Shah, and Kinjal Siddharth Jhave
Hester Biosciences Promoter Reclassification Postal Ballot
Hester Biosciences initiates postal ballot for reclassifying promoters Ravin Gandhi and Bela Gandhi to public shareholders.
The resolution seeks shareholder approval for reclassification of 803,955 sh
Hester Biosciences Promoters Reclassified to Public Category
Hester Biosciences intimates BSE and NSE of promoter reclassification approval under SEBI LODR Regulation 31A.
NSE and BSE grant no-objection for Ravin Gandhi and Bela Gandhi's move from Promoter Grou
Panacea Biotec Promoter Gift Transfer to HUF
Dr. Rajesh Jain transfers 200,000 Panacea Biotec shares via gift to his HUF, claiming SEBI takeover regulation exemption.
The transaction was executed at zero consideration on June 12, 2026, with SEBI
Lyka Labs Promoter Kunal Gandhi Acquires 14,176 Shares
Lyka Labs promoter Kunal Gandhi acquired 14,176 equity shares via open market purchases on June 29, 2026.
The transaction value was ₹10,28,414.16, increasing his holding from 35,00,162 to 35,14,338 sh
Lyka Labs Promoters Acquire 56,000 Shares
Lyka Labs discloses promoter and promoter group open market share acquisitions totaling 56,000 equity shares.
Kunal Gandhi acquired 6,533 shares on June 25, 2026, increasing his holding to 3.5 million
Goldline Pharma Promoter Acquires 60,000 Shares
Goldline Pharmaceutical Ltd discloses promoter Swapan Khandelwal's open market purchase of 60,000 equity shares.
The acquisition represents 0.62% of total paid-up capital, increasing his holding from
Parmax Pharma PAC Acquires 2.76% Stake Off-Market
Abhay Chinubhai Shah (PAC 8) acquired 249,394 equity shares (2.76%) of Parmax Pharma on June 18, 2026 via off-market transaction.
The acquisition was made at ₹35.00 per share from three individual sel
Amanta Healthcare Promoter Bhavesh Patel Buys 4,635 Shares
• Amanta Healthcare discloses promoter Bhavesh Patel's open-market purchase of 4,635 equity shares under SEBI Insider Trading Regulations.
• The transaction, executed on NSE on June 17, 2026, had a va
Parmax Pharma PAC Acquires 53,520 Shares
Rupa Sunil Shah acquired 53,520 equity shares in Parmax Pharma via off-market transaction on June 16, 2026.
Total shareholding of acquirer and PACs increased to 7,68,320 shares, representing 20.54% of
Amanta Healthcare Promoter Sells 5,000 Shares
Amanta Healthcare discloses a promoter group member's open-market sale of 5,000 equity shares.
The transaction, valued at ₹7,86,550, reduced the promoter's holding from 2.92% to 2.91%.
The disclosure
Bharat Parenterals Promoter Buys 900 Shares
Bharat Parenterals Ltd filed a SEBI PIT Regulation 7(2) disclosure for a promoter's share acquisition.
Promoter entity Desai Shares and Stock Private Limited purchased 900 equity shares via on-market
Novartis India 26% Open Offer at ₹860.64/Share
Acquirers announce mandatory open offer for 26% of Novartis India shares at ₹860.64 per share.
Independent Directors Committee recommends the offer as fair per SEBI pricing regulations.
Tendering peri
Sudarshan Pharma Promoter Releases 20 Lakh Share Pledge
Sudarshan Pharma promoter Hemal Mehta released a pledge on 20 lakh shares, representing 0.83% of total capital.
The release was executed on June 3, 2026, and disclosed to BSE under SEBI Takeover Regul